natgillin/translations-raw huggingface dataset:
Noxafil Noxafil Noxafil
Noxafil Noxafil
Noxafil oral suspension is also used as a first-line treatment for ‘thrush’, a fungal infection of the mouth and throat due to Candida.
Oralna suspenzija Noxafil koristi se kao terapija prve linije za „mliječac”, gljivičnu infekciju usta i grla prouzročenu gljivicom Candida.
Noxafil oral suspension is taken with a meal or nutritional supplement; the suspension must be shaken well before use.
Oralna suspenzija Noxafil uzima se zajedno s obrokom ili dodacima prehrani; suspenziju treba dobro promućkati prije primjene.
Noxafil oral suspension, solution for infusion and gastro-resistant tablets are also used to prevent invasive fungal infections in patients whose immune system is weakened because of treatments they are receiving for blood or bone marrow cancers or medicines used in haematopoietic stem cell transplantation (a transplant of cells that make blood cells).
Oralna suspenzija, otopina za infuziju i gastrorezistentne tablete Noxafil također se koriste za sprječavanje invazivnih gljivičnih infekcija u bolesnika s oslabljenim imunosnim sustavom uslijed terapija koje primaju za liječenje rakova krvi ili koštane srži ili lijekova koji se koriste u transplantaciji hematopoetskih matičnih stanica (transplantaciji stanica koje stvaraju krvne stanice).
Noxafil should not be used in children (17 years of age and younger).
Noxafil se ne smije primjenjivati u djece (u dobi od 17 godina i mlađe).
Noxafil tablets can be taken with or without food and should be swallowed whole with water; the tablets should not be crushed, chewed, broken or dissolved.
Tablete Noxafil mogu se uzimati s hranom ili bez nje te se trebaju gutati cijele s vodom; tablete se ne smiju drobiti, žvakati, lomiti ili otapati.
No—never shake the vial.
Ne – nikada ne tresite bočicu.
Nplate 250 micrograms powder and solvent for solution for injection Nplate 500 micrograms powder and solvent for solution for injection Romiplostim
Nplate 250 mikrograma prašak i otapalo za otopinu za injekciju Nplate 500 mikrograma prašak i otapalo za otopinu za injekciju romiplostim
Nplate 250 micrograms powder and solvent for solution for injection:
Nplate 250 mikrograma prašak i otapalo za otopinu za injekciju:
Nplate 250 micrograms powder and solvent for solution for injection: Pre-filled syringe (type 1 clear glass with bromobutyl rubber plunger) containing 0.72 ml of water for injections for reconstitution.
Nplate 250 mikrograma prašak i otapalo za otopinu za injekciju: Napunjena štrcaljka (prozirno staklo tipa 1 s klipom od brombutilne gume) koja sadrži 0,72 ml vode za injekcije za rekonstituciju.
Nplate 250 micrograms powder for solution for injection
Nplate 250 mikrograma prašak za otopinu za injekciju
Nplate 250 micrograms powder for solution for injection Nplate 500 micrograms powder for solution for injection
Nplate 250 mikrograma prašak za otopinu za injekciju Nplate 500 mikrograma prašak za otopinu za injekciju
Nplate 250 micrograms powder for solution for injection Nplate 500 micrograms powder for solution for injection Romiplostim
Nplate 250 mikrograma prašak za otopinu za injekciju Nplate 500 mikrograma prašak za otopinu za injekciju romiplostim
Nplate 250 micrograms powder for solution for injection should be reconstituted with 0.72 ml sterile water for injections, yielding a deliverable volume of 0.5 ml.
Nplate 250 mikrograma prašak za otopinu za injekciju treba rekonstituirati s 0,72 ml sterilne vode za injekcije, kako bi se dobio korisni volumen od 0,5 ml.
Nplate 500 micrograms powder and solvent for solution for injection:
Nplate 500 mikrograma prašak i otapalo za otopinu za injekciju:
Nplate 500 micrograms powder and solvent for solution for injection: Pre-filled syringe (type 1 clear glass with bromobutyl rubber plunger) containing 1.2 ml of water for injections for reconstitution.
Nplate 500 mikrograma prašak i otapalo za otopinu za injekciju: Napunjena štrcaljka (prozirno staklo tipa 1 s klipom od brombutilne gume) koja sadrži 1,2 ml vode za injekcije za rekonstituciju.
Nplate 500 micrograms powder for solution for injection
Nplate 500 mikrograma prašak i otapalo za otopinu za injekciju
Nplate 500 micrograms powder for solution for injection
Nplate 500 mikrograma prašak za otopinu za injekciju
Nplate 500 micrograms powder for solution for injection should be reconstituted with 1.2 ml sterile water for injections, yielding a deliverable volume of 1 ml.
Nplate 500 mikrograma prašak za otopinu za injekciju treba rekonstituirati s 1,2 ml sterilne vode za injekcije kako bi se dobio volumen od 1 ml.
Nplate 500 micrograms powder for solution for injection should be reconstituted with 1.2 ml sterile water for injections, yielding a deliverable volume of 1 ml.
Nplate 500 mikrograma prašak za otopinu za injekciju treba rekonstituirati s 1,2 ml sterilne vode za injekcije, kako bi se dobio korisni volumen od 1 ml.
Nplate has been compared with placebo (a dummy treatment) in two main studies involving adults with long-term ITP.
Nplate je uspoređen s placebom (prividnim liječenjem) u okviru dvaju glavnih ispitivanja koja su obuhvaćala odrasle osobe s kroničnim ITP-om.
Nplate is a sterile but unpreserved product and is intended for single use only.
Nplate je sterilan, ali nekonzerviran lijek namijenjen za jednokratnu uporabu.
Nplate is a white powder for solution for injection supplied in a 5 ml glass vial.
Nplate je bijeli prašak za otopinu za injekciju dostupan u staklenoj bočici od 5 ml.
Nplate is available with or without a solvent.
Nplate je dostupan s otapalom ili bez njega.
Nplate is used in adults with long-term immune thrombocytopenic purpura (ITP), a disease in which the patient’s immune system destroys the platelets (components in the blood that help it to clot).
Nplate se primjenjuje u odraslih osoba s kroničnom imunom trombocitopeničnom purpurom (ITP-om), bolesti kod koje imunosni sustav bolesnika uništava trombocite (tjelešca u krvi koja potiču grušanje).
Nplate is used in patients who have already been treated with medicines such as corticosteroids or immunoglobulins and who have had their spleen removed, if these treatments have not worked.
Nplate se primjenjuje u bolesnika u kojih ne djeluje terapija lijekovima poput kortikosterioda ili imunoglobulina.
Nplate is used to treat adult patients (aged 18 years and over) who may or may not have had their spleen removed for chronic ITP and who have been previously treated with corticosteroids or immunoglobulins, where these treatments don’t work.
Nplate se koristi za liječenje odraslih bolesnika (starih 18 godina i više) kojima može i ne mora biti odstranjena slezena zbog kroničnog ITP-a te koji su već bili neuspješno liječeni kortikosteroidima ili imunoglobulinima.
Nplate is used to treat adult patients (aged 18 years and over) who may or may not have had their spleen removed for chronic ITP and who have been previously treated with corticosteroids or immunoglobulins, where these treatments don’t work.
Nplate se koristi za liječenje odraslih bolesnika (starih 18 godina i više) kojima može i ne mora biti odstranjena slezena zbog kroničnog ITP-a, te koji su već bili neuspješno liječeni kortikosteroidima ili imunoglobulinima.
Nplate must not be used in people who are hypersensitive (allergic) to romiplostim, any of the other ingredients, or proteins produced by Escherichia coli (a bacterium).
Nplate se ne smije primjenjivati u osoba koje su preosjetljive (alergične) na romiplostim, bilo koji drugi sastojak ili na proteine koje proizvodi bakterija Escherichia coli.
Nplate single- use vial
Nplate bočica za jednokratnu primjenu
Nplate was more effective than placebo at increasing blood platelet counts.
Nplate se pokazao učinkovitijim od placeba u povećavanju broja trombocita.
Nplate’s active ingredient is romiplostim, which is a protein used to treat low platelet counts in patients with immune (idiopathic) thrombocytopenic purpura (called ITP).
Djelatna tvar u lijeku Nplate je romiplostim, protein koji se koristi za liječenje sniženog broja trombocita u bolesnika s imunološkom (idiopatskom) trombocitopeničnom purpurom (skraćeno ITP).
Npn stands for non-protein-nitrogen such as urea, uric acid, amino acid, etc.
Npn označava neproteinski dušik, npr. ureu, mokraćnu kiselinu, aminokiseline itd.
NR
ND
NR
NP
NR = Not reached
NP = Nije postignut
NR = not reached; NA = not available; HCM = hypercalcaemia of malignancy; SMR = skeletal morbidity rate; HR = Hazard Ratio; RRR = Relative Risk Reduction †Adjusted p-values are presented for Studies 1, 2 and 3 (first SRE and first and subsequent SRE endpoints); *Accounts for all skeletal events over time; only events occurring ≥ 21 days after the previous event are counted.
NP = nije postignuto; ND = nije dostupno; HCM = hiperkalcijemija maligne bolesti; SSM = stopa skeletnog morbiditeta; HR = Omjer hazarda; RRR = Redukcija Relativnog Rizika †Prilagođene p-vrijednosti predstavljene su za Ispitivanja 1, 2 i 3 (mjere ishoda: prvi SRE i prvi i sljedeći SRE); *Odnosi se na sve koštane događaje tijekom vremena; samo događaji nakon ≥ 21 dana od prethodnog događaja su uračunati.
NR – not reported
NP – nije prijavljeno
NR**
NP
NR, not reached.
ND, nije dostignut
NR: not reached; n.a.: not applicable
ND: nije dostignuto; n.p.: nije primjenjivo
NRT vs Placebo
Placebo
NRT=Nicotine replacement therapy patch
Psihijatrijska kohorta N=4074
NRTI backbone
Osnovno liječenje NRTI-jem
NRTIs and NNRTIs
Lijekovi klase NRTI i NNRTI
NRTIs and NNRTIs
NRTI i NNRTI
NRTIs/Efavirenz
Antibiotici
NRTIs/Efavirenz
NRTI/efavirenz
NR∞
ND∞
NS3-4A protease inhibitors
NS3-4A inhibitori proteaze
NS3/4A protease inhibitors (PI)
Inhibitori NS3/4A proteaze (IP)
NS5A RAVs were overrepresented in patients who experienced relapse in the Phase 3 studies (see “Clinical efficacy and safety”).
Početni NS5A RAV bili su više zastupljeni u pacijenata koji su u ispitivanjima faze 3 imali relaps (vidjeti dio „Klinička djelotvornost i sigurnost“).
NS5A RAVs were seen at relapse in 5/5 patients (for genotype 1a: Q30R/H + L31M/V [n = 1] and Q30R [n = 1]; for genotype 1b: Y93H [n = 3]).
U relapsu su u 5/5 pacijenata opaženi NS5A RAV-ovi (za genotip 1a: Q30R/H + L31M/V [n = 1] i Q30R [n = 1]; za genotip 1b: Y93H [n = 3]).
NS5A RAVs were seen at the time of relapse in 11/13 patients (for genotype 1a: Q30R alone [n = 2], Y93C [n = 1], Y93H/C
NS5A RAV-ovi su u vrijeme relapsa bili opaženi u 11/13 pacijenata (za genotip 1a: samo Q30R
NS: not studied. a.
NS: nije ispitano. a.
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non- selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.
NSAIL (tj. acetilsalicilna kiselina u protuupalnim režimima doziranja, COX-2-inhibitori i neselektivni NSAIL) mogu smanjiti antihipertenzivni učinak antagonista receptora angiotenzina II.
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non- selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.
NSAIL-i (tj. acetilsalicilatna kiselina u protuupalnim režimima doziranja, COX-2 inhibitori i neselektivni NSAIL-i) mogu smanjiti antihipertenzivan učinak antagonista receptora angiotenzina II.
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non- selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.
NSAIL-i (tj. acetilsalicilna kiselina u protuupalnim režimima doziranja, COX-2 inhibitori i neselektivni NSAIL-i) mogu smanjiti antihipertenzivan učinak antagonista receptora angiotenzina II.
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non- selective NSAIDs) may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II receptor antagonists.
NSAIL (tj. acetilsalicilna kiselina u protuupalnim režimima doziranja, COX-2 inhibitori i neselektivni NSAIL) mogu reducirati diuretski, natriuretski i antihipertenzivni učinak tiazidskih diuretika te antihipertenzivni učinak antagonista receptora angiotenzina II.
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non- selective NSAIDs) may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II receptor antagonists.
NSAIL-i (tj. acetilsalicilna kiselina u protuupalnim režimima doziranja, COX-2 inhibitori i neselektivni NSAIL-i) mogu reducirati diuretski, natriuretski i antihipertenzivni učinak tiazidskih diuretika te antihipertenzivni učinak antagonista receptora angiotenzina II.
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.
NSAIL (tj. acetilsalicilna kiselina u protuupalnim režimima doziranja, COX-2-inhibitori i neselektivni NSAIL) mogu smanjiti antihipertenzivni učinak antagonista receptora angiotenzina II.
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs) may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II receptor antagonists.
NSAIL-i (tj. acetilsalicilna kiselina u protuupalnim režimima doziranja, COX-2 inhibitori i neselektivni NSAIL-i) mogu reducirati diuretski, natriuretski i antihipertenzivni učinak tiazidskih diuretika te antihipertenzivni učinak antagonista receptora angiotenzina II.
NSAIDs (non steroidal anti-inflammatory medicines, e.g. acetylsalicylic acid or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
NSAIL-i (nesteroidni protuupalni lijekovi, npr. acetilsalicilatna kiselina ili ibuprofen), heparin, imunosupresivi (npr. ciklosporin ili takrolimus) i antibiotik trimetoprim.
NSAIDs (non steroidal anti-inflammatory medicines, e.g. acetylsalicylic acid or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
NSAIL-i (nesteroidni protuupalni lijekovi, npr. acetilsalicilna kiselina ili ibuprofen), heparin, imunosupresivi (npr. ciklosporin ili takrolimus) i antibiotik trimetoprim.
NSAIDs do not have any anti-microbial properties.
NSAIL-i nemaju antimikrobna svojstva.
NSAIDs or acetylsalicylic acid (ASA)), and in patients with known bleeding tendencies.
NSAIL ili acetilsalicilatna kiselina (ASK)) te u bolesnica s poznatom sklonošću krvarenjima.
NSAIDs or acetylsalicylic acid (ASA)), and in patients with known bleeding tendencies.
NSAIL ili acetilsalicilatna kiselina (ASK)) te u bolesnika s poznatom sklonošću krvarenjima.
NSAIDs or acetylsalicylic acid (ASA)), and in patients with known bleeding tendencies.
NSAIL, acetilsalicilatna kiselina (ASK)) te u bolesnika s poznatom sklonošću krvarenjima.
NSAIDs should be used with caution in these patients.
U tih bolesnika valja oprezno primjenjivati topikalne NSAIL-e.
NSAIDs) or can potentially lead to haematopoietic disorders.
NSAIL-ovi) ili mogu potencijalno dovesti do hematopoetskih poremećaja.
NSAIDs, including Dynastat, may make it more difficult to become pregnant.
Nesteroidni protuupalni lijekovi uključujući Dynastat mogu Vam otežati da zatrudnite.
NSAIDs: NSAIDs given for short-term perioperative analgesia have been shown not to be associated with increased bleeding risk when given in conjunction with dabigatran etexilate.
NSAIL-i: Pokazalo se da NSAIL-i koji se daju radi kratkotrajne perioperativne analgezije nisu povezani s povećanim rizikom od krvarenja kada se daju istodobno uz dabigatraneteksilat.
NSAIDs: NSAIDs given for short-term perioperative analgesia have been shown not to be associated with increased bleeding risk when given in conjunction with dabigatran etexilate.
NSAIL: Pokazalo se da NSAIL koji se daju radi kratkotrajne perioperativne analgezije nisu povezani s povećanim rizikom od krvarenja kada se daju istodobno uz dabigatraneteksilat.
NSAIDs: NSAIDs given for short-term perioperative analgesia have been shown not to be associated with increased bleeding risk when given in conjunction with dabigatran etexilate.
NSAIL: Pokazalo se da NSAIL-i koji se daju radi kratkotrajne perioperativne analgezije nisu povezani s povećanim rizikom od krvarenja kada se daju istodobno uz dabigatraneteksilat.
NSCLC patients with recent pulmonary bleeding (>2.5 ml or bright red blood) as well as patients with evidence of baseline tumour cavitation, regardless of histology, or those with any evidence of tumour invasion or encasement of major blood vessels have been excluded from clinical trials (see section 4.3).
U klinička ispitivanja nisu bili uključeni bolesnici oboljeli od NSCLC-a s nedavnim plućnim krvarenjem (> 2,5 ml ili svjetlocrvena krv), bolesnici u kojih su na početku ispitivanja postojali dokazi kavitacije tumora, neovisno o histološkom tipu, kao ni bolesnici u kojih su na početku ispitivanja postojali bilo kakvi dokazi da je tumor prodro ili okružio velike krvne žile (vidjeti dio 4.3).
NSCLC treatment after failure of at least one prior chemotherapy regimen (Tarceva administered as monotherapy):
Liječenje NSCLC nakon neuspjeha primjene barem jednog kemoterapijskog protokola (Tarceva primijenjena kao monoterapija):
NSCLC, first-line treatment:
Rak pluća nemalih stanica, prva linija liječenja:
NSCLC, maintenance treatment
Rak pluća nemalih stanica, terapija održavanja:
NSCLC, maintenance treatment JMEN
Rak pluća nemalih stanica, terapija održavanja: JMEN
NSCLC, maintenance treatment:
Rak pluća nemalih stanica, terapija održavanja:
NSCLC, maintenance treatment: JMEN
NSCLC, terapija održavanja JMEN
NSCLC, second-line treatment:
NSCLC, prva linija liječenja
NSCLC: studies CA209017, CA209057 and CA209026
NSCLC: ispitivanja CA209017, CA209057 i CA209026
NSF may result in debilitating joint immobility, muscle weakness or may affect the normal working of internal organs which may potentially be life-threatening.
Posljedice NSF-a mogu biti nepokretnost zglobova, mišićna slabost ili utjecaj na rad unutrašnjih organa, koje potencijalno mogu ugroziti život.
NT-proBNP (% reduction)
N- terminal proBrain Natriuremic Peptide) (% smanjenja)
nts
nice
Nucala
Nucala Nucala
Nucala can reduce your number of asthma attacks, if you are already using medicines such as high dose inhalers, but your asthma is not well controlled by these medicines.
Nucala može smanjiti broj napadaja astme koje imate, ako već uzimate lijekove poput inhalatora s visokim dozama lijeka, ali Vam astma nije dobro kontrolirana tim lijekovima.
Nucala contains the active substance mepolizumab.
Nucala sadrži djelatnu tvar mepolizumab.
Nucala does not contain a preservative therefore reconstitution should be carried out under aseptic conditions.
Nucala ne sadrži konzervans te se stoga rekonstitucija mora provoditi u aseptičkim uvjetima.
Nucala is an asthma medicine used to treat adults with a particular type of asthma called eosinophilic asthma.
Nucala je lijek protiv astme koji se koristi za liječenje odraslih s posebnom vrstom astme zvanom eozinofilna astma.
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients (see section 5.1).
Nucala je indicirana kao dodatna terapija u liječenju teške refraktorne eozinofilne astme u odraslih bolesnika (vidjeti dio 5.1).
Nucala is intended for long- term treatment.
Nucala je namijenjena za dugoročno liječenje.
Nucala should be prescribed by a doctor experienced in identifying and treating severe eosinophilic asthma, and can only be obtained with a prescription.
Lijek Nucala treba propisati liječnik iskusan u dijagnosticiranju i liječenju teške eozinofilne astme, te se izdaje samo na liječnički recept.
Nucala should be prescribed by physicians experienced in the diagnosis and treatment of severe refractory eosinophilic asthma.
Lijek Nucala moraju propisati liječnici s iskustvom u dijagnosticiranju i liječenju teške refraktorne eozinofilne astme.
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Nukleo(z/t)idni inhibitori reverzne transkriptaze (NRTI)
Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine.
Analozi nukleozida i nukleotida mogu u različitom stupnju utjecati na funkciju mitohondrija, a taj je utjecaj najizraţeniji uz stavudin, didanozin i zidovudin.
Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine.
Analozi nukleozida i nukleotida mogu, u različitom stupnju, utjecati na funkciju mitohondrija, a taj je utjecaj najizraženiji uz stavudin, didanozin i zidovudin.
Nucleoside analogs
Analozi nukleozida
Nucleoside analogue DNA polymerase inhibitors
Nukleozidni inhibitori DNA polimeraze
Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Analozi nukleozida i nukleotida pokazali su u in vitro i in vivo uvjetima pokazali sposobnost uzrokovanja različitih stupnjeva mitohondrijskih oštećenja.
Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Pokazalo se da analozi nukleozida i nukleotida uzrokuju različiti stupanj mitohondrijskog oštećenja in vitro i in vivo.
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)
Nukleozidni i nukleotidni inhibitori reverzne transkriptaze (NRTI)
Nucleoside Naive
Prethodno neliječeni analozima nukleozida
Nucleoside naïve patients: the recommended dose in adults is 0.5 mg once daily, with or without food.
Bolesnici prethodno neliječeni analozima nukleozida: preporučena doza za odrasle je 0,5 mg jednom dnevno s hranom ili bez nje.
Nucleoside naïve patients: the recommended dose in adults is 0.5 mg once daily, with or without food.
Bolesnici prethodno neliječeni analozima nukleozida: preporučena doza za odrasle je 0,5 mg jednom dnevno, s hranom ili bez nje.
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs/N[t]RTIs)
Nukleozidni i nukleotidni inhibitori reverzne transkriptaze (NRTI / N[t]RTI)
Nucleoside Reverse Transcriptase Inhibitors
Nukleozidni inhibitori reverzne transkriptaze
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Inhibitori nukleozidne reverzne transkriptaze (NRTI)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Nukleozidni inhibitori reverzne transkriptaze (NRTI)
Nucleoside-naive:
Prethodno neliječeni analozima nukleozida:
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI))
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI-jevi)
Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs)
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI; engl. nucleoside/nucleotide reverse transcriptase inhibitor
Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs)
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI; engl. nucleoside/nucleotide reverse transcriptase inhibitor)
Nucleoside/tide reverse transcriptase inhibitors
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze
Nucleoside/tide reverse transcriptase inhibitors (NRTIs)
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI)
Nucleotide change
c.1102 G>A
Nucleotide change
c.215 T>G
Nucleotide change
c.911 G>C
Nucleotide change
c.G1102A
Nucleotide change
c.G911C
Nucleotide change
c.T215G
NUEDEXTA may cause dizziness.
NUEDEXTA može prouzročiti omaglicu.
NUEDEXTA should not be used in children and adolescents below the age of 18 years.
Lijek NUEDEXTA ne smiju uzimati djeca i adolescenti mlađi od 18 godina.
Null responders*** in parent study (52)
Bolesnici bez ikakvog odgovora*** u izvornom ispitivanju (52)
null responders, were randomised to EBR + GZR with or without RBV for 8, 12 or
Ispitanici su bili randomizirani u ispitivane skupine u omjeru 1:1.
NULOJIX 250 mg powder for concentrate belatacept
NULOJIX 250 mg prašak za koncentrat belatacept
NULOJIX 250 mg powder for concentrate for solution for infusion
NULOJIX 250 mg prašak za koncentrat za otopinu za infuziju